Over the last 25 years, a swine vesicular disease (SVD) has occurred in Italy mainly subclinic. Therefore, regular tests of faecal samples from suspected assets and high rolling premises were fundamental to identifying the circulation of the virus and performing SVD eradication. In this study, we evaluated the diagnostic performance of six genomic amplification methods, using positive fecal samples of 78 different epidemics (1997-2014), which included different lines. Comparison of three RT-PCRS, designed to amplify the same part of 154 NT of the 3D gene, demonstrated that a conventional and real-time test based on the Sybr green detection test showed the highest diagnostic sensitivity, detecting All samples, while real-time Taqman-based test failed three cases due to two incompatibles in the target sequence of the probe.
The specificities of diagnosis and analysis were optimal because 300 negative field samples and other enteroviruses reacted negative. Three other tests evaluated, previously described, were an inverse isothermal amplification on the 3D reverse transcriptase (Lamp RT) and two real-time RT-PCR targeting on the region of 5’UTR. Here, the presence of multiple imbalances in the probe and the primers reduced the diagnostic performance and two of the analyzes could not detect viruses of a sub-lineage. These results emphasize that the choice of tests using fewer nucleotide objectives has contributed considerably to the success of the SVD eradication plan. Acanthamoeba is a living amoeba of extended genetic diversity. This can cause infectious keratitis (IK), which can also be caused by bacteria, fungi and viruses. A high diagnostic sensitivity is essential for establishing early diagnosis of the keratitis associated with Acanthamoeba. Here we have studied the applicability of new generation sequencing (NGS) – detection of ribosomal genes and the differentiation of ribosomal genes (16s-18) (16s-18) with respect to a specific real-time PCR for detection of 'Acanthamoeba Two hundred dna corneal rappings extracts and projected by Acanthamoeba-specific. Real-time PCR has been analyzed using an internal NGS dosage.
The joint regression model (JRM) is used to describe the changes in the trend in many applications and relies on the detection of participation points (changePoints). However, the methods of detecting existing join points, namely the search methods of the grid (GS) – are demanding in a manner comprising and, consequently, the maximum number of calculable join points is limited. In this document, we have developed a sealing model of the genetic algorithm (GAJP) in which an explicitly decoupled computer procedure for optimization and regression is used to integrate a binary genetic algorithm into the JRM for optimal detection point of participation. The combinations of participation points were represented in the form of binary chromosomes and genetic operations were carried out to determine the optimal solution by minimizing the Fitness function, the Bayesian information criterion (BIC) and BIC3.
New genome sequence detection via natural vector convex hull method
It remains difficult to find existing but undiscovered genome sequence mutations or predicting the potential mutations of genome sequence based on actual sequence data. Motivated by this, we develop approaches to detect new non-discovered genome sequences. Because the discovery of new genome sequences through biological experiments is with high resource intensity, we want to achieve the new genome sequence detection task mathematically.
However, little literature tells us how to detect new non-discovered genome sequence mutations mathematically. We form a new frame based on a natural vector convex hull method that performs an alignment-free sequence analysis. Our newly developed approaches, random algorithm permutation with penalty (rap) and random algorithm permutation with sanction and costrising search (RAPCOS), use the properties of geometry captured by natural vectors. In our experience, we discover a genome sequence of mathematically human immunodeficiency of human immunodeficiency using certain real HIV genome sequences. Significantly, the proposed methods are applicable to the resolution of the new genome sequence detection challenge and many good properties, such as robustness, fast convergence and rapid calculation.

In situ detection of adeno-associated viral vector genomes with fish-fish
Gene therapy with recombinant inviolized virus vectors (AAV) is a promising modality for the treatment of various human diseases. Nevertheless, there are still important gaps in our understanding of the biology of AAV vectors, because in part to the lack of robust methods to follow the Capsides and genomes AAV. In this study, we describe a new application of the amplification of the fluorescence exchange of the in situ hybridization fluorescence exchange (saber-fish) which allowed the visualization and quantification of individual AAV genomes after the administration of Vector in the mouse.
SuperLight™ Dual Luciferase Reporter Gene Assay Kit |
|||
SLDL-100 | BioAssay Systems | 100 | 189 EUR |
Description: Bioluminescent reagent system for rapid quantitation of firelfy and Ranilla luciferase reporter gene expression in transfected cells. Key Features: High sensitivity and wide detection range. Detection of as little of 2 fg luciferase. Compatible with routine laboratory and HTS formats. Assays can be performed in tubes or microplates, and measured with any luminometer. Can be readily automated on HTS liquid handling systems. Fast and convenient. Three step assay allows detection of dual luciferase levels within 20 minutes. Method: Luminescence. Samples: Cells etc. Species: All. Procedure: Assay takes 20 min. Kit size: 100 tests. Detection limit: 2 fg luciferase. |
|||
Amplite® Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12518 | AAT Bioquest | 1 plate | 166 EUR |
Amplite® Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12519 | AAT Bioquest | 10 plates | 446 EUR |
Amplite® Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12520 | AAT Bioquest | 100 plates | 3321 EUR |
Amplite® Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12518-1plate | AAT Bioquest | 1 plate | 166 EUR |
Description: Common reporter genes include beta-galactosidase, beta-glucuronidase and luciferase. |
|||
Amplite® Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12519-10plates | AAT Bioquest | 10 plates | 446 EUR |
Description: Common reporter genes include beta-galactosidase, beta-glucuronidase and luciferase. |
|||
Amplite® Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12520-100plates | AAT Bioquest | 100 plates | 3321 EUR |
Description: Common reporter genes include beta-galactosidase, beta-glucuronidase and luciferase. |
|||
Amplite® Gaussia Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12530 | AAT Bioquest | 1 plate | 222 EUR |
Amplite® Gaussia Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12531 | AAT Bioquest | 10 Plates | 846 EUR |
Amplite® Gaussia Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12532 | AAT Bioquest | 100 plates | 4447 EUR |
Amplite® Renilla Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12535 | AAT Bioquest | 1 plate | 222 EUR |
Amplite® Renilla Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12536 | AAT Bioquest | 10 plates | 1070 EUR |
Amplite® Renilla Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12537 | AAT Bioquest | 100 plates | 4447 EUR |
Amplite® Gaussia Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12530-1plate | AAT Bioquest | 1 plate | 222 EUR |
Description: Common reporter genes include beta-galactosidase, beta-glucuronidase and luciferase. |
|||
Amplite® Gaussia Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12531-10Plates | AAT Bioquest | 10 Plates | 846 EUR |
Description: Common reporter genes include beta-galactosidase, beta-glucuronidase and luciferase. |
|||
Amplite® Gaussia Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12532-100plates | AAT Bioquest | 100 plates | 4447 EUR |
Description: Common reporter genes include beta-galactosidase, beta-glucuronidase and luciferase. |
|||
Amplite® Renilla Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12535-1plate | AAT Bioquest | 1 plate | 222 EUR |
Description: Common reporter genes include beta-galactosidase, beta-glucuronidase and luciferase. |
|||
Amplite® Renilla Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12536-10plates | AAT Bioquest | 10 plates | 1070 EUR |
Description: Common reporter genes include beta-galactosidase, beta-glucuronidase and luciferase. |
|||
Amplite® Renilla Luciferase Reporter Gene Assay Kit *Bright Glow* |
|||
12537-100plates | AAT Bioquest | 100 plates | 4447 EUR |
Description: Common reporter genes include beta-galactosidase, beta-glucuronidase and luciferase. |
|||
Luciferase Reporter Assay Kit |
|||
55R-1540 | Fitzgerald | 200 assays | 294 EUR |
Description: Assay Kit for detection of Luciferase Reporter in the research laboratory |
|||
Luciferase Reporter Assay Kit |
|||
K801-200 | Biovision | each | 235.2 EUR |
Luciferase Reporter Assay Kit |
|||
K2181-200 | ApexBio | 200 assays | 217.2 EUR |
Dual Luciferase Reporter Assay Kit |
|||
DL101-01 | Vazyme | 100 rxn | 309.6 EUR |
Single-Luciferase Reporter Assay Kit |
|||
20-abx098133 | Abbexa |
|
|
Double-Luciferase Reporter Assay Kit |
|||
20-abx098134 | Abbexa |
|
|
ARE Luciferase Reporter Lentivirus |
|||
79869 | BPS Bioscience | 500 µl x 2 | 875 EUR |
Description: The Nrf2 antioxidant response pathway plays an important role in the cellular antioxidant defense. Nrf2, a basic leucine zipper transcription factor, induces the expression of antioxidant and phase II enzymes by binding to the ARE (antioxidant response element) region of the gene promoter. Under basal conditions, Nrf2 is retained in the cytosol by binding to the cytoskeletal protein Keap1. Upon exposure to oxidative stress or other ARE activators, Nrf2 is released from Keap1 and translocates to the nucleus, where it can bind to the ARE, leading to the expression of antioxidant and phase II enzymes that protect the cell from oxidative damage. The ARE Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by ARE located upstream of the minimal TATA promoter. After transduction, activation of the Nrf2 antioxidant response pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
SRE Luciferase Reporter Lentivirus |
|||
78627 | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The SRE (Serum Response Element) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the Serum Response Element located upstream of the minimal TATA promoter . After transduction, activation of the MAPK/ERK signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
Myc Luciferase Reporter Lentivirus |
|||
78628 | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The Myc Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the Myc response element located upstream of the minimal TATA promoter and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the Myc signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
UAS Luciferase Reporter Lentivirus |
|||
78631 | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The UAS (Upstream Activation Sequence) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by a multimerized GAL4 upstream activation sequence (UAS) located upstream of the minimal TATA promoter and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the UAS-controlled signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
p53 Luciferase Reporter Lentivirus |
|||
78666 | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The p53 Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by p53 response elements located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, p53-regulated gene expression in the target cells can be monitored by measuring the luciferase activity. |
|||
HRE Luciferase Reporter Lentivirus |
|||
78668 | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The Hypoxia Response Element (HRE) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by four copies of a hypoxia response elements (HRE) located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the induction of hypoxia in the target cells can be monitored by measuring the luciferase activity. |
|||
TEAD Luciferase Reporter Lentivirus |
|||
79833 | BPS Bioscience | 500 µl x 2 | 875 EUR |
Description: The Hippo pathway regulates cell proliferation and cell death. It is activated by high cell density and cell stress to stop cell proliferation and induce apoptosis. The mammalian Hippo pathway comprises MST kinases and LATS kinases. When the Hippo pathway is activated, MST kinases phosphorylate LATS kinases, which phosphorylate transcriptional co-activators YAP and TAZ. Unphosphorylated YAP and TAZ remain in nucleus and interact with TEAD/TEF transcriptional factors to turn on cell cycle-promoting gene transcription. However, when phosphorylated, YAP and TAZ are recruited from the nucleus to the cytosol, so that the YAP and TAZ-dependent gene transcription is turned off. Dysfunction of the Hippo pathway is frequently detected in human cancer and its down-regulation correlates with the aggressive properties of cancer cells and poor prognosis. The TEAD Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the TEAD response elements located upstream of the minimal TATA promoter. After transduction, activation of the Hippo pathway in the target cells can be monitored by measuring the luciferase activity._x000D_ |
|||
STAT3 Luciferase Reporter Lentivirus |
|||
79744 | BPS Bioscience | 500 µl x 2 | 860 EUR |
Description: The STAT3 Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene under the control of STAT3-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the STAT3 signaling pathway in the target cells can be monitored by measuring the luciferase activity._x000D_ |
|||
STAT5 Luciferase Reporter Lentivirus |
|||
79745 | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The STAT5 Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene under the control of STAT5-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the STAT5 signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
NF-κB Luciferase Reporter Lentivirus |
|||
79564 | BPS Bioscience | 500 µl x 2 | 875 EUR |
Description: The NF-κB Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by four copies of the NF-κB response element located upstream of the minimal TATA promoter. After transduction, activation of the NF-κB signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
Bald VSV Delta G (Luciferase Reporter) |
|||
78636-1 | BPS Bioscience | 100 µl | 395 EUR |
Description: The bald VSV Delta G (Luciferase Reporter) was produced without envelope glycoproteins. It contains the firefly luciferase gene as the reporter. The bald VSV Delta G (Luciferase Reporter) can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors. |
|||
Bald VSV Delta G (Luciferase Reporter) |
|||
78636-2 | BPS Bioscience | 500 µl x 2 | 1995 EUR |
Description: The bald VSV Delta G (Luciferase Reporter) was produced without envelope glycoproteins. It contains the firefly luciferase gene as the reporter. The bald VSV Delta G (Luciferase Reporter) can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors. |
|||
CRE/CREB Luciferase Reporter Lentivirus |
|||
79580 | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The main role of the cAMP response element, or CRE, is mediating the effects of Protein Kinase A (PKA) by way of transcription. Upon phosphorylation, CREB forms a functionally active dimer that binds the CRE element within the promoters of target genes and activates transcription. CRE is at the focus of many extracellular and intracellular signaling pathways, including cAMP, calcium, GPCR (G-protein coupled receptors) and neurotrophins. The cAMP/PKA signaling pathway is critical to numerous life processes in living organisms.The CRE/CREB Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by multimerized cAMP response element (CRE) located upstream of the minimal TATA promoter. After transduction, activation of the cAMP/PKA signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
Single-Luciferase (Renilla) Reporter Assay Kit |
|||
20-abx298011 | Abbexa |
|
|
NFAT Luciferase-RFP Reporter Lentivirus |
|||
78617-H | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The NFAT Luciferase-RFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase and RFP (Red Fluorescent Protein) cassette driven by the NFAT response element located upstream of the minimal TATA promoter and a hygromycin or puromycin selection gene to generate stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity or RFP expression. RFP fluoresces red-orange when excited; it has an excitation wavelength of 553 nm, and an emission wavelength of 574 nm. |
|||
NFAT Luciferase-RFP Reporter Lentivirus |
|||
78617-P | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The NFAT Luciferase-RFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase and RFP (Red Fluorescent Protein) cassette driven by the NFAT response element located upstream of the minimal TATA promoter and a hygromycin or puromycin selection gene to generate stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity or RFP expression. RFP fluoresces red-orange when excited; it has an excitation wavelength of 553 nm, and an emission wavelength of 574 nm. |
|||
STAT3 Luciferase Reporter THP-1 Cell Line |
|||
78498 | BPS Bioscience | 2 vials | 1900 EUR |
Description: The STAT3 Luciferase Reporter THP-1 cell line is designed for monitoring the STAT3 signal transduction pathway. It contains a firefly luciferase gene driven by STAT3 response elements located upstream of the minimal TATA promoter. After activation by cytokines or growth factors, endogenous STAT3 binds to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
IL-2 Luciferase Reporter Jurkat cell line |
|||
60481 | BPS Bioscience | 2 vials | 6875 EUR |
Description: Human IL-2 reporter construct is stably integrated into the genome of Jurkat T-cells. The firefly luciferase gene is controlled by a human IL-2 promoter. |
|||
IL-2 Promoter Luciferase Reporter Lentivirus |
|||
79825 | BPS Bioscience | 500 µl x 2 | 795 EUR |
Description: The IL-2 Promoter Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the human IL-2 promoter. After transduction, activation of the IL-2 signaling pathway in the target cells can be monitored by measuring the luciferase activity._x000D_ |
|||
IL-8 Promoter Luciferase Reporter Lentivirus |
|||
79827 | BPS Bioscience | 500 µl x 2 | 795 EUR |
Description: The IL-8 Promoter Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the human IL-8 promoter. After transduction, activation of the IL-8 signaling pathway in the target cells can be monitored by measuring the luciferase activity._x000D_ |
|||
GIPR/CRE Luciferase Reporter HEK293 Cell Line |
|||
78589 | BPS Bioscience | 2 vials | 10105 EUR |
Description: Recombinant HEK293 cells expressing the firefly luciferase gene under the control of cAMP response element (CRE), and with forced expression of human GIPR (Gastric Inhibitory Polypeptide receptor; NM_000164.4). Activation of GIPR in these cells can be monitored by measuring luciferase activity._x000D_The functionality of the GIPR/CRE Luciferase Reporter HEK293 Cell Line was validated in a dose-response assay using agonists gastric inhibitory peptide (GIP) and tirzepatide hydrochloride. These agonists induce luciferase activity in a dose-dependent manner as depicted in Figure 1._x000D_
|
|||
Bald Lentiviral Pseudovirion (Luciferase Reporter) |
|||
79943 | BPS Bioscience | 500 µl x 2 | 875 EUR |
Description: The bald lentiviral pseudovirion was produced without envelope glycoproteins such as VSV-G or SARS-CoV-2 spike. It contains the firefly luciferase gene driven by a CMV promoter as the reporter. The bald lentiviral pseudovirion can serve as a negative control when studying virus entry initiated by specific interactions between virus particles and receptors._x000D_ |
|||
NFAT Reporter (Luciferase) - THP-1 Cell Line |
|||
78320 | BPS Bioscience | 2 vials | 1810 EUR |
Description: The NFAT reporter (Luciferase)-THP-1 cell line is designed for monitoring the NFAT (nuclear factor of activated T-cells) signaling pathway in THP-1 cells by measuring luciferase activity. It contains a firefly luciferase gene driven by the NFAT response element located upstream of the minimal TATA promoter. Upon activation by NFAT activators such as Ionomycin, endogenous NFAT transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. |
|||
NFAT Luciferase Reporter Lentivirus-79579-G |
|||
79579-G | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The NFAT Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the NFAT response element located upstream of the minimal TATA promoter (Figure 1) and an antibiotic selection gene (hygromycin, puromycin, or G418) for the selection of stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
NFAT Luciferase Reporter Lentivirus-79579-H |
|||
79579-H | BPS Bioscience | 500 µl x 2 | 860 EUR |
Description: The NFAT Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the NFAT response element located upstream of the minimal TATA promoter and an antibiotic selection gene (hygromycin or puromycin) for the selection of stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
NFAT Luciferase Reporter Lentivirus-79579-P |
|||
79579-P | BPS Bioscience | 500 µl x 2 | 860 EUR |
Description: The NFAT Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by the NFAT response element located upstream of the minimal TATA promoter and an antibiotic selection gene (hygromycin or puromycin) for the selection of stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
CGRPR/CRE Luciferase Reporter HEK293 Cell Line |
|||
78325 | BPS Bioscience | 2 vials | 10340 EUR |
Description: Recombinant HEK293 cell line stably expressing full-length human Calcitonin receptor-like receptor (CALCRL/CRLR/CLR; accession number: NM_005795) and containing a firefly luciferase gene under the control of multimerized cAMP response element (CRE). This cell line can be used to measure the EC50 and IC50 of CALCRL agonists and antagonists using the luciferase reporter activity. |
|||
GR-GAL4 Luciferase Reporter Jurkat Cell Line |
|||
78525 | BPS Bioscience | 2 vials | 2275 EUR |
Description: The Glucocorticoid Receptor (GR)-GAL4 Luciferase Reporter Jurkat Cell Line contains an engineered transcription factor stably integrated into the genome of Jurkat cells, which consists of the glucocorticoid receptor ligand binding domain fused to the DNA binding domain of GAL4. This fusion construct activates firefly luciferase expression which is under the control of a multimerized GAL4 upstream activation sequence (UAS). This allows for specific detection of glucocorticoid-induced activation of the glucocorticoid receptor without the need for individual transcriptional targets and with low cross-reactivity for other nuclear receptor pathways. This cell line is validated for response to stimulation of dexamethasone and to the treatment with mifepristone, an inhibitor of the glucocorticoid signaling pathway. |
|||
XRE Luciferase Reporter Lentivirus (AhR Signaling) |
|||
78672 | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The Xenobiotic response element (XRE) Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce most types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by three copies of an XRE located upstream of the minimal TATA promoter (Figure 1), and an antibiotic selection gene (puromycin) for the selection of stable clones. After transduction, the activation of aryl hydrocarbon receptor (AhR) in the target cells can be monitored by measuring the luciferase activity. |
|||
ADAR1 Dual Luciferase Reporter HEK293 Cell Line |
|||
78547 | BPS Bioscience | 2 vials | 19950 EUR |
Description: The ADAR1 Luciferase Reporter HEK293 cell line is designed to monitor RNA editing by Adenosine deaminase acting on RNA (ADAR1). This cell line stably expresses ADAR1 under the control of a CMV promoter and a separate ADAR editing reporter construct expressed under the control of another CMV promoter. The reporter contains the gene encoding firefly luciferase, which is constitutively expressed in the cells, upstream of the gene encoding the GluA2 ADAR substrate followed by the Renilla luciferase gene. The sequence corresponding to GluA2 has been modified to contain an amber stop codon (UAG). When edited by ADAR, this stop codon (UAG) will be changed to UIG (A to I edit), which is read as tryptophan (UGG) by the translation machinery. This edit allows translation to occur all the way to the end of the reporter mRNA and results in the expression of Renilla luciferase. Conversely, in the absence of ADAR1 activity, translation terminates at the stop codon and Renilla is not expressed. Reporter activity is read out as the Renilla Luciferase/Firefly luciferase ratio whereby inhibition of ADAR activity, and thus the UAG (stop) to UGG (tryptophan) conversion rate, will result in a dose-dependent decrease in the Renilla luciferase/Firefly luciferase ratio. |
|||
TMIGD2/NFAT Luciferase Reporter Jurkat Cell Line |
|||
78323 | BPS Bioscience | 2 vials | 10340 EUR |
Description: Recombinant Jurkat cell line expressing firefly luciferase under the control of an NFAT response element, and with constitutive expression of human TMIGD2 (Transmembrane and immunoglobulin domain containing 2; CD28H; NM_144615). Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity. |
|||
IL-15 Responsive Luciferase Reporter Cell Line |
|||
78402 | BPS Bioscience | 2 vials | 10175 EUR |
Description: This recombinant Jurkat cell line is a biologically relevant system to measure activation of the IL-15 cytokine receptor by IL-15. The cells were engineered for constitutive expression of human CD122 (IL-15Rβ; IL-2Rβ; NM_000878.4), and conditional expression of firefly luciferase driven by STAT5 response elements located upstream of the minimal TATA promoter. Expression of CD122 allows formation of a functional IL-15 receptor at the surface of Jurkat cells, which naturally express high levels of CD132 (also known as IL-15 receptor subunit γc). Activation of the STAT5 signaling pathway in response to IL-15 or IL-15 analogs can be monitored by measuring luciferase activity. |
|||
KIR3DL3/IL-2 Luciferase Reporter Jurkat Cell Line |
|||
78322 | BPS Bioscience | 2 vials | 10855 EUR |
Description: Recombinant Jurkat cell line expressing firefly luciferase under the control of an IL-2-responsive promoter, and with constitutive expression of human KIR3DL3 (Killer Cell Immunoglobulin Like Receptor, Three Ig Domains and Long Cytoplasmic Tail 3; GenBank accession #BC143802.1 corresponding to KIR3DL3*00402 allele). HHLA2 (B7-H7) mediates an immune-stimulatory signal via TMIGD2 (Transmembrane and immunoglobulin domain containing 2; CD28H) in naïve T cells while it delivers an immune-inhibitory signal through KIR3DL3 in activated T cells and Natural Killer (NK) cells. |
|||
SBE Luciferase Reporter Lentivirus (TGFβ/SMAD Pathway) |
|||
79806 | BPS Bioscience | 500 µl x 2 | 875 EUR |
Description: The SBE Luciferase Reporter Lentivirus (TGFβ/SMAD signaling pathway) are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by multimerized SBE-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the TGFβ/SMAD signaling pathway can be monitored by measuring the luciferase activity._x000D_ |
|||
NFAT Luciferase-eGFP Reporter Jurkat Cell Line |
|||
78662 | BPS Bioscience | 2 vials | 2195 EUR |
Description: Recombinant Jurkat T cells expressing both firefly luciferase and enhanced GFP (eGFP) under the control of NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway can be monitored by examining either firefly luciferase or eGFP expression. |
|||
VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78634-1 | BPS Bioscience | 100 µl | 795 EUR |
Description: The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility. |
|||
VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78634-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
Description: The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) was produced by re-expression of VSV-G as the envelope glycoprotein using the VSV Delta G system in which VSV-G is deleted. The pseudovirions contain the firefly luciferase gene; therefore, the VSV-G mediated cell entry can be measured via luciferase activity. The VSV-G Pseudotyped VSV Delta G (Luciferase Reporter) can be used as a positive control of transduction for other VSV pseudotypes containing the envelope glycoproteins of heterologous viruses in a Biosafety Level 2 facility. |
|||
Hippo Pathway TEAD Luciferase Reporter MCF7 cell line |
|||
60618 | BPS Bioscience | 2 vials | 2445 EUR |
Description: The TEAD Reporter - MCF7 cell line contains the firefly luciferase gene under the control of TEAD responsive elements stably integrated into the human breast cancer cell line, MCF7. Inside the cells, basal unphosphorylated YAP/TAZ remains in the nucleus and induces the constitutive expression of luciferase reporter. The cell line is validated for the inhibition of the expression of luciferase reporter by the activators of the Hippo pathway. |
|||
B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line |
|||
78363 | BPS Bioscience | 2 vials | 11095 EUR |
Description: B2M (Beta-2-Microglobulin) has been genetically removed by CRISPR/Cas9 genome editing from NFAT Luciferase Reporter Jurkat cells. Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity. |
|||
AP1 Luciferase Reporter Lentivirus (JNK Signaling Pathway) |
|||
79823 | BPS Bioscience | 500 µl x 2 | 795 EUR |
Description: The stress-activated protein kinase/c-jun N-terminal kinase (SAPK/JNK) family of proteins includes mitogen-activated protein kinases (MAPKs) that are activated by stress, inflammatory cytokines, mitogens, oncogenes, and inducers of cell differentiation and morphogenesis. Upon activation of the SAPK/JNK pathway, MAP Kinase Kinases phosphorylate and activate JNKs. The activated JNKs translocate to the nucleus where they phosphorylate and activate transcription factors such as c-Jun. c-Jun then binds to the activator protein-1 (AP1) response element and induces AP1 transcription. The AP1 Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by AP1 response element located upstream of the minimal TATA promoter. After transduction, activation of the JNK signaling pathway and AP1 mediated activity in the target cells can be monitored by measuring the luciferase activity. |
|||
Minicircle Single Reporter: EF1 Luciferase DNA (30 µg) |
|||
BLIV511MC-1 | SBI | 30 ug | 652 EUR |
Anti-BCMA CAR Jurkat/NFAT (Luciferase) Reporter Cell Line |
|||
79694 | BPS Bioscience | 2 vials | 9400 EUR |
Description: The anti-BCMA CAR Jurkat/NFAT-luciferase reporter cell line is a stable cell line made from the anti-BCMA scFV CAR lentivirus (BPS Bioscience #79701). It has been validated for anti BCMA-CAR expression by FACS, and for functional activation stimulated by both soluble BCMA protein (BPS Bioscience #79467) and BCMA/CHO target cells (BPS Bioscience #79500). |
|||
NFAT Luciferase-eGFP Reporter Lentivirus-78656-G |
|||
78656-G | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The NFAT Luciferase-eGFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase and eGFP cassette driven by the NFAT response element located upstream of the minimal TATA promoter (Figure 1) and a puromycin selection gene to generate stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity or eGFP expression. |
|||
NFAT Luciferase-eGFP Reporter Lentivirus-78656-P |
|||
78656-P | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The NFAT Luciferase-eGFP Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase and eGFP cassette driven by the NFAT response element located upstream of the minimal TATA promoter (Figure 1) and a puromycin selection gene to generate stable clones. After transduction, activation of the NFAT signaling pathway in the target cells can be monitored by measuring the luciferase activity or eGFP expression. |
|||
TCR/B2M Knockout NFAT Luciferase Reporter Jurkat Cell Line |
|||
78557 | BPS Bioscience | 2 vials | 16695 EUR |
Description: This cell line is a double knockout of TCR (T Cell Receptor) and B2M (Beta-2-Microglobulin). First, the TRAC (T-Cell Receptor Alpha Constant) and the TRBC1 (T-Cell Receptor Beta Constant 1) domains of the TCRα/β chains were genetically removed by CRISPR/Cas9 genome editing from NFAT Luciferase Reporter Jurkat cells to generate the TCR Knockout NFAT Luciferase Reporter Jurkat cell Line (BPS Bioscience #78556). These TCR knockout cells were used to generate a new cell line in which B2M was also genetically removed by CRISPR/Cas9 genome editing. _x000D_Expression of the firefly luciferase gene is driven by NFAT response elements located upstream of the minimal TATA promoter. Activation of the NFAT signaling pathway in these cells can be monitored by measuring luciferase activity. |
|||
CD160/NFAT - Luciferase Reporter - Jurkat Recombinant Cell Line |
|||
79594 | BPS Bioscience | 2 vials | 9400 EUR |
Description: Recombinant Jurkat T cell expressing firefly luciferase gene under the control of NFAT response elements with constitutive expression of human CD160. CD160 is a GPIanchored glycoprotein member of the Ig superfamily, also known as BY55, NK1, and NK28. GenBank Accession # NM_007053._x000D__x000D_ |
|||
GAS Luciferase Reporter Lentivirus (IFN-γ/JAK/STAT1 Pathway) |
|||
78653 | BPS Bioscience | 500 µl x 2 | 835 EUR |
Description: The GAS Luciferase Reporter Lentiviruses are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to transduce almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by three copies of the interferon gamma (IFN-γ) activated sites (GAS) located upstream of the minimal TATA promoter and a puromycin selection gene for the selection of stable clones. After transduction, the GAS-regulated gene expression in the target cells can be monitored by measuring the luciferase activity. |
|||
ISRE Luciferase Reporter Lentivirus (JAK/STAT Signaling Pathway) |
|||
79824 | BPS Bioscience | 500 µl x 2 | 820 EUR |
Description: The JAK/STAT pathway is activated by various cytokines and growth factors and plays a critical role in cell growth, hematopoiesis, and immune response. In mammals, there are four JAKs (JAK1, JAK2, JAK3 and TYK2) and seven STAT proteins. IFNα is a Type I interferon. Binding of IFNα to its receptor leads to the activation of JAK1 and TYK2, which in turn phosphorylate and activate STAT1 and STAT2. The phosphorylated STAT1 and 2 form a heterodimer and bind to IRF9/p48, forming a protein complex ISGF3. This complex translocates to the nucleus and binds to the ISRE (Interferon Stimulated Response Element) in the promoter region, thereby promoting transcription of interferon-inducible genes. The ISRE Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene driven by multimerized ISRE response element located upstream of the minimal TATA promoter. After transduction, the activity of Type I interferon-induced JAK/STAT signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
79942-1 | BPS Bioscience | 100 µl | 875 EUR |
Description: The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_ |
|||
Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
79942-2 | BPS Bioscience | 500 µl x 2 | 4405 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_ |
|||
RARα Reporter Cellular Assay Pack |
|||
79322 | BPS Bioscience | 2 vials | 2390 EUR |
Description: The RARα Reporter Cellular Assay Pack provides all the key reagents required to monitor the activity of retinoic acid receptor alpha (RARα). The pack contains the RARα Reporter (Luc)-HEK293 Cell Line, a luciferase reporter cell line that contains a firefly luciferase gene under the control of retinoic acid response elements stably integrated into HEK293 cells along with full length human RARα (GenBank Accession No. NM_000964). This cell line is functionally validated for the response to the stimulation of all-trans retinoic acid, and the expression of RARα is confirmed by Western blotting._x000D_Additionally, the pack includes cell culture medium (Thaw Medium 6) that has been optimized for use with HEK293 cells. Thaw Medium 6 includes 10% fetal bovine serum and 1% Pen/Strep. Finally, the pack provides the ONE-Step™ Luciferase Detection System. This reagent provides highly sensitive, stable detection of firefly (Photinus pyralis) luciferase activity. The ONE-Step luciferase reagent can be used directly in cells in growth medium, and can be detected with any luminometer; automated injectors are not required. |
|||
RARβ Reporter Cellular Assay Pack |
|||
79323 | BPS Bioscience | 2 vials | 2050 EUR |
Description: The RARβ Reporter Cellular Assay Pack provides all the key reagents required to monitor the activity of retinoic acid receptor beta (RARβ). The pack contains the RARβ Reporter (Luc)-HEK293 Cell Line, a luciferase reporter cell line that contains a firefly luciferase gene under the control of retinoic acid response elements stably integrated into HEK293 cells along with full length human RARα (GenBank Accession No. P10826-2). This cell line is functionally validated for the response to the stimulation of all-trans retinoic acid, and the expression of RARβ is confirmed by Western blotting._x000D_Additionally, the pack includes cell culture medium (Thaw Medium 6) that has been optimized for use with HEK293 cells. Thaw Medium 6 includes 10% fetal bovine serum and 1% Pen/Strep. Finally, the pack provides the ONE-Step™ Luciferase Detection System. This reagent provides highly sensitive, stable detection of firefly (Photinus pyralis) luciferase activity. The ONE-Step luciferase reagent can be used directly in cells in growth medium, and can be detected with any luminometer; automated injectors are not required. |
|||
RARγ Reporter Cellular Assay Pack |
|||
79324 | BPS Bioscience | 2 vials | 2050 EUR |
Description: The RARγ Reporter Cellular Assay Pack provides all the key reagents required to monitor the activity of retinoic acid receptor gamma (RARγ). The pack contains the RARγ Reporter (Luc)-HEK293 Cell Line, a luciferase reporter cell line that contains a firefly luciferase gene under the control of retinoic acid response elements stably integrated into HEK293 cells along with full length human RARα (GenBank Accession No. P13631-1). This cell line is functionally validated for the response to the stimulation of all-trans retinoic acid, and the expression of RARγ is confirmed by Western blotting._x000D_Additionally, the pack includes cell culture medium (Thaw Medium 6) that has been optimized for use with HEK293 cells. Thaw Medium 6 includes 10% fetal bovine serum and 1% Pen/Strep. Finally, the pack provides the ONE-Step™ Luciferase Detection System. This reagent provides highly sensitive, stable detection of firefly (Photinus pyralis) luciferase activity. The ONE-Step luciferase reagent can be used directly in cells in growth medium, and can be detected with any luminometer; automated injectors are not required. |
|||
Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78637-1 | BPS Bioscience | 100 µl | 795 EUR |
Description: The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3.The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices. |
|||
Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78637-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
Description: The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike corresponding to the initial strain (Genbank Accession #QHD43416.1) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility.The Spike (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6, Calu-3, and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G are preferred for use in cells such as Vero-E6 and Calu-3.The infectivity of VSV-Delta G pseudotypes is restricted to a single round of replication, therefore the pseudotypes can be handled using BSL-2 containment practices. |
|||
Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78642-1 | BPS Bioscience | 100 µl | 795 EUR |
Description: The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 D614G variant in a Biosafety Level 2 facility.The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells. |
|||
Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78642-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
Description: The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1; with D614G mutation) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 D614G variant in a Biosafety Level 2 facility.The Spike (D614G) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells. |
|||
TCF/LEF Luciferase Reporter Lentivirus (Wnt/β-catenin Signaling Pathway) |
|||
79787 | BPS Bioscience | 500 µl x 2 | 875 EUR |
Description: The TCF/LEF Luciferase Reporter Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types of mammalian cells, including primary and non-dividing cells. The particles contain a firefly luciferase gene under the control of TCF/LEF-responsive element located upstream of the minimal TATA promoter. After transduction, activation of the Wnt/β-catenin signaling pathway in the target cells can be monitored by measuring the luciferase activity. |
|||
Spike Variants (SARS-CoV-2) Pseudotyped Lentivirus Pack (Luciferase Reporter) |
|||
78616 | BPS Bioscience | 12 x 100 µl | 2795 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against the viral infection. Numerous SARS-CoV-2 variants have been identified so far. These variants contain a number of mutations that may increase morbidity and mortality and allow the virus to spread more easily and quickly than the original strain.BPS Bioscience has launched a series of Spike Variants (SARS-CoV-2) Pseudotyped Lentivirus (Luc reporter). The Spike (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike Variant (see below for mutation details) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike Variants (SARS-CoV-2) Pseudotyped Lentivirus Pack (Luciferase Reporter) contains a collection of 12 Spike variants (SARS-CoV-2) Pseudotyped lentivirus (Luc reporter). It is a great tool to screen for variant-specific antibodies or to test the binding or efficacy of drug candidates against the different Spike variants. The Spike (SARS-CoV-2) pseudotyped lentiviruses can be used to measure the activity of neutralizing antibody against SARS-CoV-2 infection in a Biosafety Level 2 facility. |
|||
NF-κB Reporter Cellular Assay Pack (CHOK1) |
|||
79325 | BPS Bioscience | 2 vials | 1245 EUR |
Description: The NF-κB Reporter Cellular Assay Pack provides all the key reagents required to monitor the activity of the nuclear factor Kappa B (NF-κB) signal transduction pathways. The pack contains the NF-κB Reporter (Luc)- CHO-K1 Recombinant Cell Line, a luciferase reporter cell line that contains a firefly luciferase gene under the control of four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. This cell line is validated for the response to TNFalpha and to treatment with NF-κB inhibitor, evodiamine. _x000D_Additionally, the pack includes cell culture medium (Thaw Medium 3) that has been optimized for use with CHO-K1 cells. Thaw Medium 3 includes 10% fetal bovine serum and 1% Pen/Strep. Finally, the pack provides the ONE-Step™ Luciferase Detection System. This reagent provides highly sensitive, stable detection of firefly (Photinus pyralis) luciferase activity. The ONE-Step luciferase reagent can be used directly in cells in growth medium, and can be detected with any luminometer; automated injectors are not required. |
|||
NF-κB Reporter Cellular Assay Pack (HCT116) |
|||
79326 | BPS Bioscience | 2 vials | 1245 EUR |
Description: The NF-κB Reporter Cellular Assay Pack provides all the key reagents required to monitor the activity of the nuclear factor Kappa B (NF-κB) signal transduction pathways. The pack contains the NF-κB Reporter (Luc)- HCT-116 Recombinant Cell Line, a luciferase reporter cell line that contains a firefly luciferase gene under the control of four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. This cell line is validated for the response to TNFalpha and to treatment with NF-κB inhibitor, evodiamine._x000D_Additionally, the pack includes cell culture medium (Thaw Medium 7) that has been optimized for use with HCT-116 cells. Thaw Medium 7 includes 10% fetal bovine serum and 1% Pen/Strep. Finally, the pack provides the ONE-Step™ Luciferase Detection System. This reagent provides highly sensitive, stable detection of firefly (Photinus pyralis) luciferase activity. The ONE-Step luciferase reagent can be used directly in cells in growth medium, and can be detected with any luminometer; automated injectors are not required._x000D__x000D_ |
|||
NF-κB Reporter Cellular Assay Pack (HEK293) |
|||
79327 | BPS Bioscience | 2 vials | 1515 EUR |
Description: The NF-κB Reporter Cellular Assay Pack provides all the key reagents required to monitor the activity of the nuclear factor Kappa B (NF-κB) signal transduction pathways. The pack contains the NF-κB Reporter (Luc)-HEK293 Recombinant Cell Line, a luciferase reporter cell line that contains a firefly luciferase gene under the control of four copies of the NF-κB response element located upstream of the minimal TATA promoter. After activation by pro-inflammatory cytokines or stimulants of lymphokine receptors, endogenous NF-κB transcription factors bind to the DNA response elements, inducing transcription of the luciferase reporter gene. This cell line is validated for the response to TNFalpha and to treatment with NF-κB inhibitor, evodiamine._x000D_Additionally, the pack includes cell culture medium (Thaw Medium 1) that has been optimized for use with HEK293 cells. Thaw Medium 1 includes 10% fetal bovine serum, non-essential amino acids, sodium pyruvate, and 1% Pen/Strep. Finally, the pack provides the ONE-Step™ Luciferase Detection System. This reagent provides highly sensitive, stable detection of firefly (Photinus pyralis) luciferase activity. The ONE-Step luciferase reagent can be used directly in cells in growth medium, and can be detected with any luminometer; automated injectors are not required._x000D_ |
|||
Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-100 µl |
|||
78641-1 | BPS Bioscience | 100 µl | 795 EUR |
Description: The Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.1.1 variant in a Biosafety Level 2 facility.As shown in Figures 1 and 2, the Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in BA.1.1 Omicron Variant:A67V, Δ69-70, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, T95I, Q954H, N969K, L981F |
|||
Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter)-500 µl x 2 |
|||
78641-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
Description: The Spike (BA.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.1.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.1.1 variant in a Biosafety Level 2 facility._x000D_As shown in Figures 1 and 2, the Spike (BA.1.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based spike pseudoviruses for use in cells such as Vero-E6 parental cells._x000D_Spike Mutations in BA.1.1 Omicron Variant:_x000D_A67V, Δ69-70, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, T95I, Q954H, N969K, L981F |
|||
Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78640-1 | BPS Bioscience | 100 µl | 795 EUR |
Description: The Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Delta B.1.617.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based Spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in B.1.617.2 Delta Variant:T19R, G142D, del156/157, R158G, L452R, T478K, D614G, P681R, D950N |
|||
Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78640-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
Description: The Spike (B.1.617.2, Delta Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Delta B.1.617.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 B.1.617.2 variant in a Biosafety Level 2 facility.The Spike (B.1.617.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred over lentiviral-based Spike pseudoviruses for use in cells such as Vero-E6 parental cells.Spike Mutations in B.1.617.2 Delta Variant:T19R, G142D, del156/157, R158G, L452R, T478K, D614G, P681R, D950N |
|||
Spike (BQ.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78697-1 | BPS Bioscience | 100 µl | 835 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BQ.1 omicron variant has additional mutations (K444T and N460K) based on the BA.5 variant. The Spike (BQ.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BQ.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BQ.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BQ.1 variant in a Biosafety Level 2 facility._x000D_
|
|||
Spike (BQ.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78697-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BQ.1 omicron variant has additional mutations (K444T and N460K) based on the BA.5 variant. The Spike (BQ.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BQ.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BQ.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BQ.1 variant in a Biosafety Level 2 facility._x000D_
|
|||
Spike (BQ.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78698-1 | BPS Bioscience | 100 µl | 835 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BQ.1.1 omicron variant has additional mutations (R346T, K444T and N460K) based on the BA.5 variant. The Spike (BQ.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BQ.1.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BQ.1.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BQ.1.1 variant in a Biosafety Level 2 facility._x000D_
|
|||
Spike (BQ.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78698-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BQ.1.1 omicron variant has additional mutations (R346T, K444T and N460K) based on the BA.5 variant. The Spike (BQ.1.1, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BQ.1.1 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BQ.1.1, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BQ.1.1 variant in a Biosafety Level 2 facility._x000D_
|
|||
Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78699-1 | BPS Bioscience | 100 µl | 835 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BF.7 omicron variant has additional mutation R346T based on the BA.5 variant. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BF.7 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BF.7 variant in a Biosafety Level 2 facility._x000D_
|
|||
Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78699-2 | BPS Bioscience | 500 µl x 2 | 4195 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of October 2022, several new BA.5 sub-lineages (e.g. BQ.1, BQ.1.1, BF.7) have been designated._x000D_The spike protein of BF.7 omicron variant has additional mutation R346T based on the BA.5 variant. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BF.7 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BF.7, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron BF.7 variant in a Biosafety Level 2 facility._x000D_
|
|||
Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78736-1 | BPS Bioscience | 100 µl | 875 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of January 2023, additional new sub-lineages (e.g. BQ.1, BQ.1.1, BF.7, XBB.1, XBB.1.5) have been designated._x000D_The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron XBB.1.5 variant in a Biosafety Level 2 facility._x000D_
|
|||
Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter) |
|||
78736-2 | BPS Bioscience | 500 µl x 2 | 4405 EUR |
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and human ACE2 may offer protection against the viral infection. Omicron Variant was identified in South Africa in November of 2021. This variant has a large number of mutations that allow the virus to spread more easily and quickly than other variants. As of May 2022, Omicron variants were divided into seven distinct sub-lineages: BA.1, BA.1.1, BA.2, BA.3, BA.2.12.1, BA.4, and BA.5. As of January 2023, additional new sub-lineages (e.g. BQ.1, BQ.1.1, BF.7, XBB.1, XBB.1.5) have been designated._x000D_The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) Pseudotyped Lentiviruses were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the XBB.1.5 mutations; see below for details) as the envelope glycoprotein instead of the commonly used VSV-G. These pseudovirions contain the firefly luciferase gene driven by a CMV promoter (Figure 1), therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (XBB.1.5, Omicron Variant) (SARS-CoV-2) pseudovirus can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 Omicron XBB.1.5 variant in a Biosafety Level 2 facility._x000D_
|
|||
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78635-1 | BPS Bioscience | 100 µl | 795 EUR |
Description: The Spike (BA.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.2 variant in a Biosafety Level 2 facility. |
|||
Spike (BA.2, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78635-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
Description: The Spike (BA.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene; therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.2 variant in a Biosafety Level 2 facility. |
|||
Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78643-1 | BPS Bioscience | 100 µl | 795 EUR |
Description: The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2.12.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2.12.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.2.12.1 variant in a Biosafety Level 2 facility._x000D_The Spike (BA.2.12.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred for use in cells such as Vero-E6 and Calu-3._x000D_Spike Mutations in BA.2.12.1, Omicron Variant:_x000D_T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, S704L, N764K, D796Y, Q954H, N969K |
|||
Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78643-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
Description: The Spike (BA.2.12.1, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.2.12.1 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.2.12.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.2.12.1 variant in a Biosafety Level 2 facility._x000D_The Spike (BA.2.12.1 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred for use in cells such as Vero-E6 and Calu-3._x000D_Spike Mutations in BA.2.12.1, Omicron Variant:_x000D_T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, S704L, N764K, D796Y, Q954H, N969K |
|||
Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ) |
|||
79853 | BPS Bioscience | 2 vials | 10340 EUR |
Description: Anti-CD19 CAR/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR and NFAT-luciferase reporter. It is made from the anti-CD19 CAR lentivirus (BPS Bioscience #79851). The reporter cell line has been validated for anti CD19-CAR expression by FACS, and for luciferase reporter activation stimulated by target cells including CD19/CHO recombinant cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing in primary T cells. Anti-CD19 CAR consists of anti-CD19 scFv linked to 3rd generation CAR (Chimeric Antigen Receptor) containing CD28, 4-1BB co-stimulatory domains, and CD3ζ signaling domain. |
|||
Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78644-1 | BPS Bioscience | 100 µl | 795 EUR |
Description: The Spike protein of BA.4 and BA.5 variants of SARS-CoV-2 have identical mutations. In this datasheet, the spike protein of BA.4 and BA.5 are referred to as BA.4/5._x000D_The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.4/5 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.4/5 variant in a Biosafety Level 2 facility._x000D_The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred for use in cells such as Vero-E6 and Calu-3._x000D_Spike Mutations in BA.4/5, Omicron Variant:_x000D_Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
|||
Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) |
|||
78644-2 | BPS Bioscience | 500 µl x 2 | 3995 EUR |
Description: The Spike protein of BA.4 and BA.5 variants of SARS-CoV-2 have identical mutations. In this datasheet, the spike protein of BA.4 and BA.5 are referred to as BA.4/5._x000D_The Spike (BA.4/5, Omicron Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) was produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1 containing all the Omicron BA.4/5 mutations; see below for details) as the envelope glycoprotein instead of VSV-G. The pseudovirions contain the firefly luciferase gene, therefore, the spike-mediated cell entry can be measured via luciferase activity. The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) can be used to measure the activity of a neutralizing antibody against SARS-CoV-2 BA.4/5 variant in a Biosafety Level 2 facility._x000D_The Spike (BA.4/5 Variant) (SARS-CoV-2) Pseudotyped VSV Delta G (Luciferase Reporter) has been validated for use with target cells Vero-E6 and ACE2-HEK293 (BPS Bioscience #79951). Spike VSV Delta G is preferred for use in cells such as Vero-E6 and Calu-3._x000D_Spike Mutations in BA.4/5, Omicron Variant:_x000D_Del69-70, T19I, LPPA24-27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K |
|||
Anti-CD19 CAR negative control/ NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28 transmembrane motif) |
|||
79854 | BPS Bioscience | 2 vials | 1650 EUR |
Description: Anti-CD19 CAR negative control/NFAT-luciferase reporter Jurkat cell line is a double stable cell line expressing anti-CD19 CAR negative control and NFAT-luciferase reporter. The anti-CD19 CAR negative control consists of anti-CD19 scFv linked to the CD28 transmembrane motif without any intracellular signaling domains. The reporter cell line has been validated for anti- CD19 expression by FACS, while the stimulation by target cells including CD19/CHO recombinant cell line has not activated the luciferase reporter gene in this cell line. The cell line can be used for the negative control of anti-CD19 CAR/Jurkat-NFAT cell line (BPS Bioscience, #79853)._x000D_ _x000D_ |
|||
TFEB promoter-luciferase reporter |
|||
PVT18227 | Lifescience Market | 2 ug | 360 EUR |
pTAL- p53- Reporter- Luc |
|||
PVT10822 | Lifescience Market | 2 ug | 361.2 EUR |
pGL3- FOXO- Reporter- Luc |
|||
PVT10792 | Lifescience Market | 2 ug | 361.2 EUR |
AP1 Reporter Kit (JNK Pathway) |
|||
60612 | BPS Bioscience | 500 rxns. | 565 EUR |
Description: The AP1 Reporter Kit is designed for monitoring the activity of the JNK signaling pathway and the transcriptional activity of AP1 in cultured cells. The kit contains a transfection-ready AP1 luciferase reporter vector. This reporter contains the firefly luciferase gene under the control of multimerized AP1 responsive elements located upstream of a minimal promoter. The AP1 reporter is premixed with a constitutively-expressing Renilla (sea pansy) luciferase vector that serves as an internal control for transfection efficiency. The kit also includes a non-inducible firefly luciferase vector premixed with constitutively-expressing Renilla luciferase vector as a negative control. The non-inducible luciferase vector contains the firefly luciferase gene under the control of a minimal promoter, without any additional response elements. The negative control is critical for determining pathway-specific effects and the background luciferase activity. |
|||
AlleleBalanced Luciferase Assay Kit |
|||
ABP-PA-ABLA001 | Allele Biotech | 100 RXNS | Ask for price |
AlleleBalanced Luciferase Assay Kit |
|||
ABP-PA-ABLA011 | Allele Biotech | 1000 RXNS | Ask for price |
Renilla Luciferase Assay Kit 2.0 |
|||
30082-1 | Biotium | 150AS | 206.4 EUR |
Description: Minimum order quantity: 1 unit of 150AS |
|||
Renilla Luciferase Assay Kit 2.0 |
|||
30082-2 | Biotium | 1000AS | 712.8 EUR |
Description: Minimum order quantity: 1 unit of 1000AS |
|||
Renilla Luciferase Assay Kit 2.0 |
|||
30082-T | Biotium | 50AS | 136.8 EUR |
Description: Minimum order quantity: 1 unit of 50AS |
|||
Firefly Luciferase Assay Kit 2.0 |
|||
30085-1 | Biotium | 150AS | 150 EUR |
Description: Minimum order quantity: 1 unit of 150AS |
|||
Firefly Luciferase Assay Kit 2.0 |
|||
30085-2 | Biotium | 1000AS | 550.8 EUR |
Description: Minimum order quantity: 1 unit of 1000AS |
|||
Firefly Luciferase Assay Kit 2.0 |
|||
30085-T | Biotium | 50AS | 130.8 EUR |
Description: Minimum order quantity: 1 unit of 50AS |
|||
LucyQ Firefly Luciferase Assay Kit |
|||
L0010-010 | GenDepot | 100 Assays | 327.6 EUR |
LucyQ Firefly Luciferase Assay Kit |
|||
L0010-100 | GenDepot | 1000 Assays | 740.4 EUR |
LucyQ Gaussia Luciferase Assay Kit |
|||
L0011-010 | GenDepot | 100 Assays | 346.8 EUR |
LucyQ Gaussia Luciferase Assay Kit |
|||
L0011-100 | GenDepot | 1000 Assays | 1132.8 EUR |
These genomes could be observed in retinal cells within 3 hours of AAV subroeting delivery, were about full length and correlated with a vector expression in photoreceptors and retinal pigment epithelium. Saber-fish has easily detected AAV genomes in the liver and muscles according to retro-orbital and intramuscular AAV injections, which respectively demonstrate its utility in different tissues. Using Saber-Fish, we also noted that retinal microglia, a type of cell deemed refractory to AAV transduction, is actually infected by several AAV serotypes, but seem to degrade AAV genomes before nuclear location. Our results show that Saber-Fish can be used to visualize in situ AAV genomes, allowing studies on AAV vector biology and tracking cells transduced after vector administration.